Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy

AIDS

Volumn 20, Issue 7, 2006, Pages 1019-1026

  Crane, Heidi M ^a,b   Van Rompaey, Stephen E ^a   Kitahata, Mari M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antiretroviral medication; Blood pressure; Cardiovascular disease; Highly active antiretroviral therapy; Hypertension

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COHORT ANALYSIS; DRUG EFFECT; FEMALE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SELF REPORT; SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD PRESSURE; BODY MASS INDEX; CD4 LYMPHOCYTE COUNT; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; HYPERTENSION; INDINAVIR; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NELFINAVIR; OLIGOPEPTIDES; OXAZINES; PYRIDINES; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RITONAVIR;

EID: 33646341246     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000222074.45372.00     Document Type: Article

References (24)

1. Bruno R, Gazzaruso C, Sacchi P, Zocchetti C, Giordanetti S, Garzaniti A, et al. High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk. J Acquir immune Defic Syndr 2002; 31:363-365.
2. Gazzaruso C, Sacchi P, Garzaniti A, Fratino P, Bruno R, Filice G. Prevalence of metabolic syndrome among HIV patients. Diabetes Care 2002; 25:1253-1254.
3. Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM. Metabolic complications associated with antiretroviral therapy. Antiviral Res 2001; 51:151-177.
4. Saves M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 34:1396-1405.
5. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
6. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
7. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003; 21:1377-1382.
8. Sattler FR, Qian D, Louie S, Johnson D, Briggs W, DeQuattro V, et al. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001; 15:2001-2010.
9. Seaberg EC, Munoz A, Lu M, Detels R, Margolick JB, Riddler SA, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19:953-960.
10. Jung O, Bickel M, Ditting T, Rickerts V, Welk T, Helm EB, et al. Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity. Nephrol Dial Transplant 2004; 19:2250-2258.
11. Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 2003; 22:731-736.
12. Chow DC, Souza SA, Chen R, Richmond-Crum SM, Grandinetti A, Shikuma C. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials 2003; 4:411-416.
13. Saves M, Chene G, Ducimetiere P, Leport C, Le Moal G, Amouyel P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37:292-298.
14. Cattelan AM, Trevenzoli M, Sasset L, Rinaldi L, Balasso V, Cadrobbi P. Indinavir and systemic hypertension. AIDS 2001; 15:805-807.
15. Hewitt R, Thompson W, Chu A, Hernandez F, Shelton M. Indinavir, not nelfinavir, is associated with systemic hypertension when compared to no protease inhibitor therapy. Eighth Conference on Retroviruses and Opportunistic Infections, Seattle, 2001 (abstract 658).
16. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193.
17. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans: a statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. Circulation 2005; 111:697-716.
18. Anon. Appendix 6. Body mass index: how to measure obesity. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, MA: National Institutes of Health; 1998. NIH Publication No. 98-4083, pp. 139-140.
19. Elliott WJ. Which blood pressure measurement is more important in the elderly? Arch Intern Med 1999; 159:1165-1166.
20. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153:598-615.
21. Khalsa A, Karim R, Mack W, Minkoff H, Cohen MH, Young M, et al. Hypertension in HIV-infected women related to HAART: women's interagency HIV study (WIHS). XI Conference on Retroviruses and Opportunistic Infections, San Francisco; 2004 (abstract 741).
22. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194-1198.
23. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290:199-206.
24. Reyes D, Lew SQ, Kimmel PL. Gender differences in hypertension and kidney disease. Med Clin North Am 2005; 89:613-630.